162 related articles for article (PubMed ID: 1446052)
1. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Lønning PE; Dowsett M; Jones A; Ekse D; Jacobs S; McNeil F; Johannessen DC; Powles TJ
Breast Cancer Res Treat; 1992; 23(1-2):57-62. PubMed ID: 1446052
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
3. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Geisler J; Johannessen DC; Anker G; Lønning PE
Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
[TBL] [Abstract][Full Text] [Related]
4. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
[TBL] [Abstract][Full Text] [Related]
5. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Dowsett M; Stein RC; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
[TBL] [Abstract][Full Text] [Related]
6. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M; Coombes RC
Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
[TBL] [Abstract][Full Text] [Related]
7. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
8. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
[TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
Lønning PE; Johannessen DC; Thorsen T
Br J Cancer; 1989 Jul; 60(1):107-11. PubMed ID: 2553085
[TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
12. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
14. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Dowsett M; Doody D; Miall S; Howes A; English J; Coombes RC
Breast Cancer Res Treat; 1999 Jul; 56(1):25-34. PubMed ID: 10517340
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Murray R; Pitt P
Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495
[TBL] [Abstract][Full Text] [Related]
16. Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer.
Dowsett M; Murray RM; Pitt P; Jeffcoate SL
Ann Clin Biochem; 1986 May; 23 ( Pt 3)():277-84. PubMed ID: 3789634
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
[TBL] [Abstract][Full Text] [Related]
18. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC
Cancer Chemother Pharmacol; 1990; 26(1):75-8. PubMed ID: 2322991
[TBL] [Abstract][Full Text] [Related]
20. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Anker GB; Refsum H; Ueland PM; Johannessen DC; Lien EA; Lonning PE
Clin Chem; 1999 Feb; 45(2):252-6. PubMed ID: 9931048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
